Review Article www.pjkd.com.pk

# Hyponatremia in Congestive Heart Failure (CHF): Harnessing the Horse with Tolvaptan

**Chaudhry Adeel Ebad**
Shifa International Hospital Islamabad, Pakistan
adeelebad@hotmail.com

## Abstract

Hyponatremia in Congestive Heart Failure (CHF) is a complex and ominous clinical entity that transcends simple electrolyte imbalance. It serves as a profound indicator of advanced neurohormonal derangement and stands as one of the most reliable predictors of morbidity and mortality in the heart failure population. While traditional loop diuretics remain the cornerstone of decongestion, they frequently exacerbate hyponatremia by causing natriuresis and further activating the renin-angiotensin-aldosterone system (RAAS), leading to a state of "diuretic resistance". Tolvaptan—an oral, selective vasopressin V_2-receptor antagonist—offers a physiologically targeted alternative. By inducing "aquaresis" (the excretion of solute-free water) rather than natriuresis, tolvaptan allows clinicians to "harness" the runaway vasopressin response. This article provides a comprehensive exploration of the pathophysiology of hypervolemic hyponatremia, the foundational clinical evidence supporting vaptan therapy, and a structured, safe approach to managing these high-risk patients.

**Keywords:** Hyponatremia, SIADH, Renin, Angiotensinogen, aldosterone, Congestive heart failure, tolvaptan, aquaporin

## Corresponding Author

Dr Chaudhry Adeel Ebad
Department of Nephrology, Shifa International Hospital, Islamabad, Pakistan.
Email: adeelebad@hotmail.com
DOI: 10.53778/pjkd101350
Received 12th March 2026 and accepted 24th March 2026 PJKD 2026;10(1):3-9

## Introduction:

Hyponatremia in Congestive Heart Failure (CHF) is a complex and ominous clinical entity that transcends simple electrolyte imbalance. It serves as a profound indicator of advanced neurohormonal derangement and stands as one of the most reliable predictors of morbidity and mortality in the heart failure population.[1,2] Hyponatremia, defined as a serum sodium concentration [Na^+] < 135 mEq/L, is the most common electrolyte disorder encountered in hospitalized patients with CHF, affecting approximately 20 % to 25 % of admissions.[3]

This prevalence highlights a critical nexus between cardiac dysfunction and renal water handling. The current review highlights the mechanism of hyponatremia among patients with Congestive heart failure and explores the role of Tolvaptan in its management.

## *The Clinical Burden of the "Diluted" Heart*

In heart failure, hyponatremia is rarely a result of true sodium deficiency; rather, it is almost exclusively a dilutional state characterized by a surplus of total body water relative to total body sodium exchangeable.[4,5]

The prognosis for a CHF patient with hyponatremia is poor. It is not merely a marker of severity but a direct contributor to complications, associated with prolonged hospital stays, exponentially

higher rates of readmission, and a significantly increased risk of in-hospital and post-discharge mortality.[2,6] For the modern clinician, managing this "runaway horse" requires a strategic paradigm shift—moving beyond fluid restriction, which is often ineffective and poorly tolerated, toward pharmacological interventions that address the underlying neurohormonal drivers of water retention.

## Pathophysiology: The Neurohormonal Cascade

The development of hyponatremia in CHF is the culmination of a "perfect storm" of neurohormonal activation, a maladaptive response to perceived volume depletion.

### *1. Reduced Effective Arterial Blood Volume (EABV)*

The defining characteristic of systolic heart failure is a reduced cardiac output, which leads to decrease in EABV (the filling of the arterial tree). This "underfilling" is sensed by high-pressure baroreceptors located in the carotid sinus and aortic arch.

### *2. Paradoxical Activation*

The body interprets the low EABV not as pump failure, but as absolute volume depletion (e.g., from hemorrhage). This perception paradoxically triggers the same compensatory mechanisms used in hypovolemia:

- Sympathetic Nervous System (SNS): Increases heart rate and contractility but also causes systemic vasoconstriction.
- Renin-Angiotensin-Aldosterone System (RAAS): Promotes sodium and water retention via aldosterone, but angiotensin II also serves as a potent vasoconstrictor and a potent stimulator of thirst and vasopressin release.[7,8]

### *3. The Non-Osmotic Release of Vasopressin*

This is the critical step in dilutional hyponatremia. Arginine Vasopressin (AVP) is normally released by the posterior pituitary primarily in response to high plasma osmolality. However, in CHF, the low EABV serves as a powerful non-osmotic stimulus for AVP secretion.[9] Angiotensin II further amplifies this release. The body "ignores" the fact that it is already fluid-overloaded and continues to secrete AVP in a desperate attempt to maintain arterial pressure.

### *4. The V_2 Receptor and Aquaporin-2*

AVP travels to the kidneys and binds to the V_2 receptors located on the basolateral membrane of the collecting duct cells.[10] This binding initiates a cAMP-mediated signaling cascade that results in the translocation of Aquaporin-2 (AQP2) water channels from intracellular vesicles to the apical membrane, Figure 1 .[11]

These AQP2 channels act like open "sluice gates," allowing free water to be reabsorbed from the tubular lumen back into the systemic circulation along an osmotic gradient. Because sodium is not reabsorbed in the collecting duct along with this water, the reabsorbed free water serves to dilute the existing serum sodium, resulting in progressive hyponatremia.[4,8]

## The Diuretic Dilemma: When the "Whip" Fails

Traditional heart failure therapy relies heavily on loop diuretics (e.g., furosemide) to achieve decongestion. These drugs act by blocking the Na^+-K^+-2Cl^- cotransporter in the thick ascending limb of the loop of Henle, forcing the excretion of these electrolytes along with water.[12]

While highly effective in "wet and warm" patients, this approach has profound limitations in the "wet and cold" (hyponatremic) patient. The loop diuretic is fundamentally a natriuretic (salt-wasting) agent. Forcing the loss of sodium in a patient who is already dilute often accelerates the decline in serum [Na^+].

This strategy often leads to a clinical "dead end":

1. Aggressive diuretic use causes further EABV depletion.
2. EABV depletion triggers even greater non-osmotic AVP release.
3. Sodium levels crash further.
4. The patient becomes "diuretic resistant"—retaining fluid despite massive diuretic doses—and progresses toward cardiorenal syndrome.[12, 13] The clinician is effectively trying to solve a free-water problem by removing salt, which triggers neurohormonal counter-regulation that ultimately defeats the decongestion effort.

## ***Harnessing the Horse: The Mechanism of Tolvaptan***

Tolvaptan is a competitive V_2-receptor antagonist. By blocking the binding of AVP to its renal receptor, it prevents the translocation of Aquaporin-2 channels. This pharmacological intervention induces aquaresis—the excretion of solute-free water.[14] Figure 1 details the mechanism of action of Tolvaptan in blocking V2 receptors




**Figure 1 :** Arginine Vasopressin signaling and Aquaporin-2 translocation in renal collecting duct and Tolvaptan mechanism of action blocking V2 receptors]

## ***The Aquaretic Advantage***

The distinction between aquaresis and natriuresis is not merely academic; it is the fundamental reason for tolvaptan's clinical utility. By blocking the V_2 receptor:

- Free Water is Excreted: Urine osmolality decreases significantly as dilute urine is produced.
- Serum Sodium Rises: As free water is shed from the body, the sodium remaining in the blood becomes more concentrated, correcting the dilutional state.[15]
- Decongestion is Achieved Without Salt Loss: Patients lose significant free-water weight and edema without the profound hypokalemia, hypomagnesemia, and risk of further RAAS/SNS activation seen with loop diuretics.[11]

Tolvaptan does not "whip" the kidney to waste salt; it "harnesses" the runaway V_2 response, re-establishing hormonal control over water balance.

## The Foundational Clinical Trials: SALT and EVEREST

### *The SALT Trials: Establishing Sodium Correction*

The efficacy of tolvaptan in correcting hyponatremia was established in the SALT-1 and SALT-2 trials (Study of Ascending Levels of Tolvaptan).[15] These studies included patients with hypervolemic (like CHF) or euvolemic hyponatremia (like SIADH).

- Primary Outcome: Tolvaptan was significantly superior to placebo in increasing serum sodium at both day 4 and day 30.
- Safety: The discontinuation rate due to adverse events was low and comparable to placebo, although xerostomia (dry mouth) and increased thirst were expectedly higher in the tolvaptan group.[15,16]

### *The EVEREST Trial: Defining the Role in Acute Heart Failure*

The landmark trial for CHF was the EVEREST study (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan), which specifically targeted patients hospitalized with acute heart failure and congestion.[1]

- Study Design: EVEREST was a complex trial with two components: short-term symptomatic global status and long-term mortality. It randomized over 4,000 patients to receive standard therapy plus either placebo or tolvaptan (started at 30 mg).
- Short-Term Findings (In-Hospital): Tolvaptan significantly improved patient-reported dyspnea and global clinical status compared to placebo. It achieved greater weight reduction (representing fluid loss) without increasing heart rate or worsening renal function.[1,11]
- Impact on Hyponatremia: Crucially, in the 25% of patients who were hyponatremic at baseline, tolvaptan highly effectively normalized serum sodium levels within the first 24 hours and maintained correction throughout the 30-day treatment period.[1]
- Long-Term Outcomes: Importantly, EVEREST showed no significant difference between tolvaptan and placebo in the long-term risk of mortality or heart failure-related hospitalizations.

The clear conclusion from EVEREST is that tolvaptan is a highly effective, safe symptomatic tool for decongestion and sodium stabilization in hospitalized CHF patients. It should be viewed as a precision instrument to optimize the stabilization phase of cardiorenal syndrome, rather than a disease-modifying therapy used for chronic, life-prolonging care like beta-blockers or ACE inhibitors.[1,17]

## Clinical Management: The "Rules of the Harness"

Tolvaptan is a potent medication. While it is physiologically elegant, its power demands strict adherence to safety protocols, primarily to avoid the catastrophic neurological consequences of rapid sodium correction.[8,18] The key is to manage the correction rate with precision.

### *1. The Dangers of "Too Much Harness": ODS*

If serum sodium is raised too quickly (the body shifts from dilute to concentrated too fast), water is osmotically drawn out of brain cells, leading to severe neurological damage known as Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis).[5,19]

- Symptom Profile: ODS typically manifests several days *after* the over-rapid correction, presenting with acute confusion, spastic quadriparesis, pseudobulbar palsy (difficulty swallowing/speaking), and potentially a "locked-in" syndrome.[4,19]
- High-Risk Thresholds: Clinicians must be acutely aware of patients at high risk for ODS:
    - Those with very low baseline sodium ([Na^+] < 120 mEq/L).
    - Patients with malnutrition, alcoholism, or advanced liver disease.
- Maximum Targeted Correction Rate: The universally accepted safe correction speed is < 10 – 12 mEq/L in 24 hours, and < 18 mEq/L in 48 hours. For the very high-risk patient, a target of < 8 mEq/L in 24 hours is often recommended.[4,5,19]

### *2. The Inpatient Requirement*

Due to the risks, all tolvaptan therapy must be initiated and up-titrated within a hospital setting where serum sodium can be monitored frequently and where countermeasures can be quickly implemented if correction occurs too rapidly.[8,18]

## ***Summary Protocol and Clinical Decision Flowchart***

To ensure maximum safety, a structured monitoring protocol should be integrated into clinical Clinical decision and monitoring flowchart: Tolvaptan for Hyponatremia in CHF Figure 2 .




**Figure 2:** Clinical decision and monitoring flowchart: Tolvaptan for Hyponatremia in CHF.

## Key Operational Constraints and Best Practices

### *1. Monitoring Specifics*

During the first 24 hours of initiation, serum [Na^+] must be drawn:

- At baseline (0 hour).
- Every 6 to 8 hours during the initial day of therapy (e.g., 6h, 12h, 18h, 24h).[8]

### *2. Liberalizing Fluids: A Critical Safety Step*

A common and dangerous mistake is to continue strict heart failure fluid restriction (e.g., < 1.5 L/day) when starting tolvaptan. Since tolvaptan removes water, the combination of restricted intake and pharmacological water loss can cause sodium levels to "skyrocket," exponentially increasing the risk of ODS. All fluid restrictions must be suspended when the first dose of tolvaptan is administered.[5,18]

### *3. Transitioning to Outpatient Care*

While tolvaptan must be started in the hospital, patients can sometimes be discharged on the medication for a short period to complete decongestion and stabilize electrolytes.

Clinicians must strictly observe the 30-day usage limit. This restriction arises from liver safety concerns identified in the long-term open-label SALT trials, where some patients developed reversible, but significant, elevations in liver transaminases (ALT/AST).[18] Regular liver function monitoring is required even for short-term therapy.

### *4. Managing Over-Correction*

If a serum [Na^+] draw reveals that correction is occurring too rapidly (e.g., a > 8 mEq/L rise in 12 hours), the "breaks" must be applied:

- Suspend the tolvaptan dose.
- Administer electrolyte-free water (e.g., D5W) intravenously.
- Consider administering desmopressin (dDAVP) to actively re-engage renal water retention.[8,19]

## *Future Directions and Conclusions*

Tolvaptan is a physiologically targeted intervention, representing a significant evolution in our ability to manage the most challenging subset of CHF patients—those who are hypervolemic, hyponatremic, and diuretic resistant. By "harnessing" the V_2 receptor "harness" that has gone slack, we can effectively tame the non-osmotic AVP response, correcting the dilutional state and alleviating the debilitating symptoms of congestion.

While EVEREST did not support tolvaptan as a mortality-reducing agent, its clinical value in improving symptoms, aiding safe decongestion, and stabilizing electrolyte profiles makes it an essential tool in the cardiovascular pharmacopeia. The key to successful, safe vaptan therapy lies in rigorous adherence to inpatient monitoring, careful patient selection, and a deep, mechanistic understanding of the neurohormonal horse we are attempting to tame.

## References

1. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA.* 2007;297(12):1319 – 1331.
2. Alawoad Z, Jensen J, Schou M, Ahmed N, Attia A, Rao S, Rahimi K, Wamil M. Redefining endpoints in heart failure clinical trials: the emerging role of wearable technologies in contemporary trial design. Heart Fail Rev. 2025;31(1):1. doi: 10.1007/s10741-025-10577-0.
3. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010.

4. Adler AJ, Verbalis JG. Disorders of water metabolism: hyponatremia and hypernatremia. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, editors. Brenner and Rector' s The Kidney. 12th ed. Philadelphia: Elsevier; 2024.p 540-594
5. Sterns, R. H. (2025). Disorders of Plasma Sodium — Causes, Consequences, and Correction. NEJM Evidence.
6. Mezzini G, Marasco S, Bertuccio A, Savioli G, Piccolella F, Racca F, Barbanera A, Vitali M. Hyponatremia Related to Neurocritical Care: Focus on Diagnosis and Therapy: A Systematic Review. Rev Recent Clin Trials. 2023;18(1):19-27. doi: 10.2174/1574887118666221208161259.
7. Shams E, Bonnice S, Mayrovitz HN. Diuretic resistance associated with heart failure. *Cureus.* 2022;14(1):e21369. doi:10.7759/cureus.21369.
8. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med.* 2013;126(10 Suppl 1):S1 – S42.
9. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol. 1986;58(3):295-9. doi: 10.1016/0002-9149(86)90065-2.
10. Rondon-Berrios H and Berl T. Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses. Front. Med. 2017;4:141. doi: 10.3389/fmed.2017.00141
11. Wang C, Xiong B, Cai L. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):164. doi: 10.1186/s12872-017-0598-y.
12. Wu L, Rodriguez M, El Hachem K, Krittanawong C. Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians. *Journal of Clinical Medicine*. 2024;13(15):4470. https://doi.org/10.3390/jcm13154470
13. Manolis AA, Manolis TA, Manolis AS. Neurohumoral Activation in Heart Failure. *International Journal of Molecular Sciences*. 2023;24(20):15472. https://doi.org/10.3390/ijms242015472
14. Park HC, Oh YK, on behalf of Polycystic Kidney Disease Study Group. Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance. Electrolyte Blood Press. 2022;20(1):10-16. https://doi.org/10.5049/EBP.2022.20.1.10
15. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-112. doi: 10.1056/NEJMoa065181. Epub 2006 Nov 14. PMID: 17105757.
16. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705 – 12. doi:10.1681/ASN.2009080857.
17. Pratama V, Budiono J, Thobari JA, Widyantoro B, Anggraeni VY and Dinarti LK. The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis. Front. Cardiovasc. Med. 2024;11:1367442. doi: 10.3389/fcvm.2024.1367442
18. Uemura Y, Shibata R, Ishikawa S, Takemoto K, Murohara T, Watarai M. Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation. Nagoya J Med Sci. 2021;83(3):431-441. doi: 10.18999/nagjms.83.3.431.
19. Akram A, Muhammad US, Ali AM, Rizvi FM. Osmotic Demyelination Syndrome Following Rapid Correction of Hyponatremia in a Young Woman: A Case Report and Review of Literature. Cureus. 2025;17(6):e86452. doi: 10.7759/cureus.86452.